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The introduction of vaccines con-taining the capsular polysaccha-
rides of N. meningitidis, S. pneumonia, 
and H. influenzae type b has driven a 
significant reduction in cases of disease 
caused by these bacteria. The polysaccha-
ride-specific antibody responses follow-
ing vaccination are well characterized, 
however less is known about the B cells 
underlying this response. Here, we sum-
marize the plasma cell (PC) and memory 
B cell (B
MEM
) responses following plain 
polysaccharide and protein-polysac-
charide conjugate vaccination, draw-
ing together studies covering a range of 
vaccines and age groups. These studies 
show that infant primary PC and B
MEM
 
responses to polysaccharide-conjugate 
vaccines are low in relation to older age 
groups but are significantly higher fol-
lowing booster doses. PC kinetics have 
generally been found to follow a similar 
pattern irrespective of vaccine type or age 
group, whereas divergent B
MEM
 responses 
have been reported following plain poly-
saccharide and conjugate vaccination. A 
degree of correlation between early B
MEM
 
responses and maintenance of protec-
tive antibody levels has been identified 
in some studies, but the relationship 
between the 2 remains unclear. Iden-
tification of the B cell subsets involved 
and the mechanisms by which they are 
induced may provide a better under-
standing of the role of B cells in main-
taining protective immunity through 
vaccination.
Introduction
Encapsulated organisms such as 
Haemophilus influenzae type b, Neisseria 
meningitidis, and Streptococcus pneumoniae 
cause a significant burden of disease 
worldwide mainly affecting individuals at 
the extremes of age.1-3 The outer surface of 
all 3 bacteria is covered by a polysaccha-
ride capsule, the composition and struc-
ture of which differs between and within 
each bacterial species. The polysaccharide 
capsule represents an important virulence 
factor, and is a major target for polysac-
charide-specific antibodies that can be 
successfully generated by vaccines.4 There 
are 2 types of vaccines against these organ-
isms which use the polysaccharide capsule 
as the vaccine antigen; plain polysac-
charide vaccines and glycoconjugate vac-
cines. Natural immunity to encapsulated 
bacteria is provided by a combination of 
physical barriers, innate immune mecha-
nisms and parts of the adaptive immune 
system including T cells and antibodies. 
Polysaccharide-containing vaccines aim to 
induce antigen-specific humoral immune 
responses, which can be quantified in 
terms of the serum antibody concentra-
tion. Antibodies are produced by B cells 
that have been triggered and activated by 
antigen and have undergone differentia-
tion into antibody-secreting plasma cells. 
Plain polysaccharide vaccines act by cross-
linking B cell receptors on the surface of 
naïve B cells, directing plasma cell pro-
duction, whereas the protein component 
of glycoconjugate vaccines recruits T cell 
help and the generation of both plasma 
and memory B cells.4 Extracellular spaces, 
which have been invaded by pathogens 
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and which are usually the place where 
they multiply, are protected by antibodies 
which kill extracellular microorganisms 
through complement-mediated bacteri-
olysis, opsonophagocytosis, or antibody-
dependent cellular cytotoxicity.
Although there are some data indicat-
ing how best to achieve high concentra-
tions of (functional) antibodies, little is 
known about the B cells that underlie 
such an immune response. Circulating 
B cells are a dynamic population and 
previous studies have defined the kinet-
ics of the B cell response and permitted 
B cell frequencies before and after immu-
nization to be related to immediate and 
medium-term antibody responses. In this 
manuscript we aim to describe the kinet-
ics (timing of responses) and magnitude of 
both polysaccharide-specific plasma cell 
(PC) and memory B cell (B
MEM
) responses 
following vaccination, summarizing data 
from previous studies in children, adoles-
cents, and adults.5-13 Table 1 shows char-
acteristics of studies describing plasma 
and memory B cell kinetics following 
glycoconjugate vaccination. Data derived 
from these studies were used to generate 
Figures 1 and 2.
B Cell Kinetics Following 
Vaccination
Plasma cell kinetics
Most studies that aimed to determine 
polysaccharide-specific B cell frequencies 
were performed using the enzyme-linked 
immunospot (ELISpot) assay. Other 
approaches such as flow-cytometry have 
only rarely proven to be helpful and are 
also costly, laborious, and difficult to per-
form on the large scale needed in clinical 
vaccine trials.14,15
PCs may be detected in peripheral 
blood using an ex-vivo ELISpot. This 
technique involves measurement of the 
frequency of antibody-secreting cells in 
peripheral blood which spontaneously 
produce antibody.6 In the steady-state, 
antigen-specific PCs in the peripheral 
blood are only present at a very low overall 
frequency in comparison to the total B cell 
population, but rise transiently following 
vaccination. PC kinetics following pri-
mary vaccination have been investigated 
in children after the first and third dose 
of a 3 dose schedule of meningococcal 
serogroup C conjugate vaccine at 2, 3, and 
4 mo of age (MenCCV).8 Following the 
first vaccination, PCs were low frequency 
but peaked at day 10 and fell to undetect-
able levels by day 30. PC responses follow-
ing the third dose were faster both in onset 
and decline, with the highest frequencies 
detected on day 4 (the first day assessed) 
Table 1. Characteristics of studies describing plasma and memory B cell kinetics following immunization with glycoconjugate vaccines
Study reference
Age
(y)
Number of 
samples
per study 
time 
point*
Vaccine Carrier protein
Number of 
priming doses
[time since last 
vaccination]
Study time points (days)
Plasma cells
Kelly et al.7 13–15 3–34 menCCV Crm197 1 [2–3 y] 0, 3, 4, 5, 6, 7, 8, 9, 10, 12, 28
Clutterbuck et al.6 28–44 6 PCV-7† Crm197 1 [1 y] 0, 6, 7, 15
Blanchard rohner et al.5 1 5–26 menCCV Crm197 3 [8 mo] 0, 2, 4, 6, 8, 9, 30
Kelly et al.8 0.17 33 menCCV Crm197 - 4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8 0.33 29 menCCV Crm197 2 [1 mo] 4, 6, 8, 10, 12, 14, 16
Memory B cells
Kelly et al.7 13–15 3–40 menCCV Crm197 1 [2–3 y] 0, 3, 4, 5, 6, 7, 28, 365
Clutterbuck et al.6 28–44 6 PCV-7† Crm197 1 [1 y] 0, 6, 7, 15, 28
Blanchard rohner et al.5 1 4–28 menCCV Crm197 3 [8 mo] 0, 2, 4, 6, 8, 9, 30
Kelly et al.8 0.17 31 menCCV Crm197 - 4, 6, 8, 10, 12, 14, 16, 30
Kelly et al.8 0.33 17 menCCV Crm197 2 [1 mo] 4, 6, 8, 12, 14, 16, 30
Perrett et al.9 7 52 menCCV tt 3 [6 y] 0, 7, 28, 365
Perrett et al.9 8 25 menCCV tt 2 [6 y] 0, 28, 365
Perrett et al.9 8.3 53 menCCV tt 1 [6 y] 0, 7, 28, 365
Perrett et al.9 9.3 30 menCCV tt 1 [6 y] 0, 28, 365
Perrett et al.9 10.3 27 menCCV tt 1 [6 y] 0, 28, 365
Perrett et al.9 11.3 27 menCCV tt 1 [6 y] 0, 28, 365
Perrett et al.9 12.1 29 menCCV tt 1 [6 y] 0, 7, 28, 365
*number of samples between study time points may differ markedly and the range is given if known, otherwise the total number of samples is shown; 
†Values from serotype 4 were used to describe plasma and memory B cell kinetics; Crm197, cross-reactive material (non- toxic recombinant form of diphthe-
ria toxin); menCCV, meningococcal serogroup C conjugate vaccine; PCV-7, 7-valent pneumococcal conjugate vaccine; tt, tetanus toxoid.
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and reaching baseline for all but one indi-
vidual by day 12. At the time of the third 
dose, germinal centers generated by the 
previous vaccine doses may still be pres-
ent, having not yet undergone the process 
of involution. Therefore, revaccination 
may continue to drive a response from 
these germinal centers, accounting for the 
early peak in plasma cells.
A small but consistent second rise of 
MenC-specific PCs was seen both in 
unprimed individuals after the first vac-
cine dose and following the third dose 
detectable at day 16 and day 12, respec-
tively.8 Although only a few samples were 
available for testing at each time point, it 
is possible that these later peaks represent 
the time of germinal center involution as 
suggested by animal data.16
Unprimed B cell responses directed at 
polysaccharides are more difficult to assess 
in adults. This is because the majority of 
vaccine-naïve adults already have pre-exist-
ing immunity to capsular polysaccharides, 
which also serve as vaccine antigens.10,13,14 
This immunity, in the form of B
MEM
 and 
serum antibody is probably acquired fol-
lowing repeated nasopharyngeal carriage 
of encapsulated bacteria. To overcome 
this problem, a novel T-dependent pro-
tein antigen for unvaccinated individuals 
in the UK, the rabies vaccine, was used to 
investigate B cell kinetics in a controlled 
setting of primary, secondary and tertiary 
immune responses.12 In this study, PCs 
peaked at day 10 following priming, with 
the most rapid and highest PC responses 
seen at day 7 following the third dose in 
the naïve group, as was observed with 
the primary polysaccharide response in 
infants. Studies of adult PC kinetics fol-
lowing influenza vaccination have also 
revealed consistent patterns of response. 
In these studies, PCs peaked at around a 
week following immunization.17-19
The PC response to a booster dose of 
a glycoconjugate vaccine is more rapid 
than following a primary dose, similar to 
the PC kinetics following repeated protein 
vaccination. The peak in PC responses 
following booster vaccination with a 
MenC glycoconjugate in 1-y-old children5 
or 13- to 15-y-old adolescents7 appeared at 
day 6, which is more rapid than following 
the first vaccine dose in infants but slower 
than that following the third dose of an 
infant primary series.8
Given as a booster dose, both plain 
polysaccharide and glycoconjugate vac-
cines produce a similar pattern of PC 
responses. No difference in polysac-
charide-specific PC kinetics was found 
between adolescents receiving a booster 
dose of MenCCV or MenC polysaccha-
ride vaccine (MenCPS).7 Furthermore, 
studies of glycoconjugate vaccines have 
demonstrated similar PC kinetics for 
both polysaccharide and carrier protein 
antigens,6,8 although one study reported 
a more rapid decrease in meningococ-
cal serogroup C (MenC) than diphtheria 
toxoid-specific PCs.5
The kinetics of PC responses to vac-
cination in primed (individuals with 
pre-existing immunity through previous 
vaccination) and unprimed children and 
adults compiled from studies reporting 
on several separate time points within 
the first month following vaccination are 
summarized in Figure 1.
Memory B cell kinetics
Culturing peripheral blood mono-
nuclear cells (PBMCs) with polyclonal 
stimulators such as a combination of 
pokeweed mitogen, S. aureus Cowan 
strain and CpG DNA induces the prolif-
eration of B
MEM
 and their differentiation 
into antibody-secreting cells which can 
be detected using the ELISpot assay.6,22 
The culture step means that the output 
of the ELISpot assay is not a direct mea-
sure of B
MEM
 frequency in the peripheral 
blood, but is useful for the comparison of 
responses between individuals and time 
points in relation to vaccination. Other 
methods such as flow cytometry or a lim-
iting dilution assay may also be used to 
enumerate antigen-specific B
MEM
, however 
labeling of polysaccharide antigens for 
flow cytometric analysis is very laborious 
and not straight forward due to potential 
Figure 1. the kinetics of the plasma cell response to polysaccharide-containing vaccines in vac-
cine primed and unprimed subjects. Data taken from studies reporting on at least 2 time points 
between baseline and 1 mo following vaccination.5-8 Values are plotted as a percentage of the 
maximum response within the observed time period and then smoothed (using a locally weighted 
polynomial regression model [method “loess”] of the ggplot2 package20 in r21) across all 4 studies 
represented by the lines for vaccine primed and unprimed infants, respectively.
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non-specific binding of B cells, and the 
limiting dilution assay is not as sensitive as 
ELISpot for B
MEM
 detection.23
B
MEM
 responses to a first infant dose 
of glycoconjugate vaccine are low, with 
MenC specific B
MEM
 only appearing at day 
14 post-vaccination with numbers close to 
the limit of detection.8 Reflecting the PC 
response, B
MEM
 responses to a third dose of 
vaccine are more rapid, becoming detect-
able at day 4.8 As described previously, 
primary B cell responses to polysaccharide 
antigens are difficult to study in adults, 
however, using rabies protein as a model 
vaccine, B
MEM
 responses in unprimed 
adults vaccinated with rabies protein vac-
cine showed similar kinetics; the first 
B
MEM
 became detectable 10 d post-vacci-
nation but appeared more rapidly follow-
ing additional doses.12
Following booster vaccination with 
a glycoconjugate vaccine at one year of 
age, B
MEM
 were shown to peak at around 
a week,5 which is similar to booster 
responses in adults primed with rabies 
vaccine.12 When booster doses of MenCPS 
and MenCCV were compared in adoles-
cents, B
MEM
 responses were more rapid and 
better sustained in those given the glyco-
conjugate vaccine as a booster.7
Compared with PC responses, B
MEM
 
responses in peripheral blood are more 
prolonged. Although frequencies of B
MEM
 
also diminish following the post-vacci-
nation peak, B
MEM
 specific to polysac-
charides6,14 as well other antigens such as 
the smallpox virus24 have been detected 
in peripheral blood months to years fol-
lowing vaccination. B
MEM
 generated in 
germinal center responses are thought to 
circulate briefly in peripheral blood before 
transiting to secondary lymphoid organs 
such as the lymph nodes or spleen where 
they persist long-term, or from where they 
continue to recirculate. 4 It is therefore 
important when interpreting the studies 
described in this paper to appreciate that 
B cells are only being measured in transit. 
There is currently limited knowledge of 
B cell activity in other compartments; 
however the inaccessibility of these tissues 
makes peripheral blood the only option in 
most cases.
Figure 2 combines data from the stud-
ies discussed in this section to summa-
rize the B
MEM
 response to vaccination in 
primed and unprimed individuals.5-9
Frequency of Polysaccharide-
Specific B Cell Responses
Although the timing of B cell responses 
seems to adhere to general patterns (Figs. 1 
and 2), the magnitude of these responses 
is more variable. In the following section 
we address the effect of factors such as the 
number of vaccine doses, age at vaccina-
tion, and vaccine type on post-vaccination 
B cell frequencies.
Plasma cell frequency following 
vaccination
As well as becoming increasingly rapid, 
the magnitude of the PC response is also 
greater with additional doses of vaccine 
after the primary dose. A greater fre-
quency of PCs is generated following the 
third dose of MenCCV than following 
the first,8 although in toddlers receiving 
their first dose of pneumococcal conjugate 
vaccine at 12 mo of age, revaccination at 
14 mo did not increase PC frequency in 
peripheral blood relative to the same time 
point (1 wk post-vaccination) at 12 mo.10
Despite showing similar kinetics, there 
are differences in the number of plasma 
cells induced by plain polysaccharide and 
glycoconjugate vaccines. In adolescents 
receiving either a booster dose of MenCCV 
or MenCPS, both of which contained the 
same quantity of polysaccharide antigen, 
the PC response was of greater magnitude 
in the glycoconjugate group, although 
there were no differences in the timing of 
responses.7 This suggests that a single sig-
nal from the polysaccharide component of 
both vaccine types is sufficient to induce 
the generation of PCs from pre-existing 
B
MEM
, but that T cell help may facilitate 
greater expansion of the PC pool.
Differences in PC frequency have also 
been reported in adults following differ-
ent combinations of the 7-valent pneumo-
coccal conjugate vaccine (PCV-7) and the 
Figure  2. the kinetics of the memory B cell response to polysaccharide-containing vaccines in 
primed and unprimed individuals. Data taken from studies reporting on at least one additional 
time point other than baseline and 1 mo post-vaccination.5-8 Values are plotted as a percentage of 
the maximum response within the observed time period and then smoothed (see Figure legend 
1; for the “unprimed” group data points were directly connected as smoothing in a similar way 
was not possible) across all 5 studies represented by the lines for vaccine primed and unprimed 
individuals, respectively.
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23-valent pneumococcal polysaccharide 
vaccine (PPV-23). In adults primed with 
PCV-7, boosting with PPV-23 resulted in 
a significantly higher PC response on day 
7 compared with boosting with PCV-7.25 
This may be because the polysaccharide 
quantity of each serotype is more than 
10 times higher in the PPV-23 compared 
with the PCV-7 or may result from uncon-
jugated polysaccharide antigens inducing 
the terminal differentiation of B
MEM
 into 
PCs, a phenomenon which will be covered 
in more detail in the discussion of B
MEM
 
responses below.
Memory B cell frequency following 
vaccination
B
MEM
 frequencies differ depending on 
the number of vaccine doses, and par-
ticularly when plain polysaccharide and 
glycoconjugate vaccines are compared in 
infants and the elderly. Greater B
MEM
 fre-
quencies have been reported following a 
3 dose8 compared with a 2 dose primary 
series11 of meningococcal conjugate vac-
cine, however in both studies less than 
30% of children still had detectable poly-
saccharide-specific B
MEM
 by 12 mo of age. 
Despite low pre-booster B
MEM
 frequency, 
robust responses have been reported fol-
lowing booster vaccination with glyco-
conjugate vaccines at 12 mo of age,5,11 
suggesting that the small pool of B
MEM
 
maintained post-priming is sufficient to 
sustain immunological memory.
The effect of age on B
MEM
 frequen-
cies has been investigated in a number 
of studies. Greater frequencies of B
MEM
 
have been found following vaccination 
in adults than in children. Twelve month 
old toddlers with little or no prior expo-
sure to encapsulated bacteria required at 
least 2 doses of PCV-7 to reach B
MEM
 fre-
quencies equivalent to those following a 
single dose in adults.10 However, all of the 
adults in this study already had detectable 
polysaccharide-specific B
MEM
 at baseline, 
likely induced by prior pneumococcal col-
onization, in effect priming the immune 
system. Another study reported that age 
at primary vaccination (ranging between 
6 mo and 34 y) with a glycoconjugate did 
not affect the induction and persistence of 
polysaccharide-specific B
MEM
.14
There are no studies describing 
B
MEM
 kinetics following plain polysac-
charide vaccination in children. Plain 
polysaccharide vaccines are thymus-inde-
pendent (T-independent) antigens, and 
are not thought to induce B
MEM
 formation. 
Instead, they are believed to act by induc-
ing extensive cross-linking of the B cell 
receptor (BCR) on marginal zone B cells 
and B1 cells, inducing an extrafollicular 
response predominantly involving PCs.26 
Children under the age of 2 y are unable 
to make an efficient immune response to 
T-independent antigens such as plain poly-
saccharide vaccines. This phenomenon is 
not well understood but present models 
suggest (1) an immaturity of most B cells, 
e.g., lack of CD21/complement receptor 2 
on neonatal B cells,27-29 (2) differences in 
activation requirements between primary 
and secondary B cells with young children 
having primary B cells that require both 
BCR signaling and T cell help for activa-
tion,30 (3) low frequency of marginal zone 
B cells,31,32 (4) lower levels of complement 
C3, and (5) immaturity of marginal zone 
dendritic cells and the marginal zone in 
young children.33
Although there are no data in infants, 
B
MEM
 responses to plain polysaccharide 
and glycoconjugate vaccines have been 
compared when given to adolescents and 
adults. In adolescents, the magnitude of 
B
MEM
 response was greater following a 
booster dose of MenCCV than a booster 
of MenCPS.34 In an adult study, vaccina-
tion with PCV-7 resulted in an increase 
in polysaccharide-specific B
MEM
 whereas 
vaccination with PPV-23 had the oppo-
site effect, causing a reduction in B
MEM
 
frequency.25 Adults over the age of 65 are 
the only population to routinely receive 
PPV-23. This vaccine appears to offer a 
degree of short-term protection against 
invasive pneumococcal disease,35 but no 
reduction in rates of pneumonia or mor-
tality.36,37 Furthermore, immunization 
with plain polysaccharide vaccines may 
reduce antibody levels induced by prior 
receipt of a polysaccharide-containing 
vaccine, an effect known as hyporespon-
siveness. This phenomenon has been dem-
onstrated in children38 and more recently 
in adults,39 although another smaller 
adult study did not identify an effect.13 
Hyporesponsiveness may be explained 
by the effect of polysaccharide vaccines 
on the B
MEM
 population. Plain polysac-
charide vaccines are thought to deplete 
the B
MEM
 pool by inducing strong BCR 
cross-linking and driving the terminal 
differentiation of these cells into PCs,25 
or by inducing apoptosis as demonstrated 
in neonatal mice primed with MenCCV 
and boosted with MenCPS.40 A recent 
study identified IgM-producing B cells 
as an important subset in the response 
to PPV-23 in young adults.41 When the 
B cell response was compared between 
young and elderly adults, elderly partici-
pants had fewer IgM positive B cells and 
an impaired IgM response to vaccination. 
A shift in B cell populations has also been 
implicated in the increased susceptibility 
of HIV-infected children to pneumococ-
cal disease.42 Here, children with HIV 
were found to have reduced numbers 
of circulating mature, naïve and rest-
ing B
MEM
, with an over-representation of 
mature, activated B cells.
Correlation of B Cell Responses 
to Antibody Concentrations
On a population scale a relation-
ship between antibody concentration 
and clinical protection has been demon-
strated, such that (functional) antibody 
concentrations are routinely used to pre-
dict vaccine efficacy in clinical vaccine 
trials. For example, the recently intro-
duced pneumococcal conjugate vaccine, 
PCV-13, was licensed on the basis of its 
ability to elicit antibody responses above 
a threshold defined by the efficacy of 
PCV-7.43 Plasma cells have been shown to 
correlate with immediate increases in anti-
body5,7 however long-term maintenance of 
serum antibody cannot be accounted for 
by transiently induced PCs. Instead, it is 
thought to rely upon B
MEM
 and long-lived 
PCs (LLPCs) induced by immunization. 
LLPCs have been identified in mice as a 
fraction of the PC population produced in 
the germinal center reaction following pro-
tein-polysaccharide vaccination.44 These 
cells persist in the bone marrow and can 
secrete antibody for prolonged periods of 
time. Support for the existence of LLPCs 
in humans comes from observations 
including the report that humans depleted 
of PC precursors (and hence circulating 
PCs) with rituximab are still able to main-
tain normal antibody levels.45 There is still 
©
20
14
 L
an
de
s 
B
io
sc
ie
nc
e.
 D
o 
no
t d
is
tri
bu
te
.
1666 Human Vaccines & Immunotherapeutics Volume 10 Issue 6
debate on the exact mechanisms of sur-
vival and maintenance of LLPCs, however 
the “imprinting lifespan” theory appears 
to best fit the observed antibody kinetics 
in humans. This theory suggests that PC 
life span is dependent on the strength of 
combined B cell signals experienced by the 
cell during the encounter with antigen.46 
Mechanisms of long-term maintenance of 
B
MEM
 are also still unclear but most likely 
rely on antigen-independent processes.47
While some studies have demonstrated 
a relationship between B
MEM
 and antibody 
concentration at various intervals after 
immunization this has not been consis-
tent for all antigens or between studies.9 
Blanchard Rohner et al. found that B
MEM
 
levels rather than antibody levels follow-
ing priming with MenCCV better dis-
criminated those with putative protective 
antibody levels at 12 mo.5 Another study 
identified a weak positive correlation 
between 5 mo B
MEM
 levels and 12 mo anti-
body concentrations for serotypes C and Y 
but not A or W in children vaccinated at 
2 and 4 mo of age with the MenACWY-
CRM
197
 conjugate vaccine.11
In the absence of pre-existing antibody, 
the secondary immune response initiated 
by memory cell populations is too slow to 
prevent infection by encapsulated bacte-
ria, which can become established within 
hours or days. Even a large B
MEM
 response 
may not guarantee protection; pneumo-
coccal conjugate vaccines have so far failed 
to provide any protection against serotype 
3 disease despite large B
MEM
 responses 
generated toward this serotype in children 
vaccinated with a serotype 3-containing 
vaccine.48
Herd immunity induced by polysac-
charide-containing vaccines is dependent 
on the presence of polysaccharide-specific 
antibody in the nasopharyngeal mucosa, 
which prevents bacterial colonization 
and carriage. The generation of antibody 
concentrations of sufficient magnitude 
to prevent colonization requires B
MEM
 
to be resident in the mucosa, however 
polysaccharide-specific B
MEM
 are not 
found in this tissue at the steady-state, 
only appearing transiently following vac-
cination.49 This may limit the duration 
of herd immunity provided by glycocon-
jugate vaccines. Protein-specific B
MEM
 
appear to persist better in the mucosa 
than polysaccharide-specific B
MEM
, per-
haps reflecting the different immunologi-
cal properties of the stimulating antigen. 
It will be interesting to compare the extent 
of herd immunity and the effects on car-
riage provided by the recently licensed 
protein-based serogroup B meningococcal 
vaccine with that provided by glycocon-
jugate vaccines for other meningococcal 
capsular groups.
Conclusions and Perspectives
The ability to detect B cells in the cir-
culation using techniques such as ELISpot 
has allowed the study of how 2 major 
B cell populations, plasma cells and 
memory B cells, respond to vaccination. 
Consistent patterns have been revealed 
applicable to a range of ages and vaccine 
types. Despite efforts to correlate periph-
eral B cell responses with antibody levels, 
only weak relationships have so far been 
identified. This is not surprising, given 
the incomplete understanding of the long-
term activity and maintenance of B cells 
following their relatively short appearance 
in peripheral blood. Further understand-
ing of the role of B cells in the post-vacci-
nation immune response requires certain 
challenges to be overcome. First, the 
ELISpot assay as it is currently performed 
suffers from the limitation that B
MEM
 can 
only be easily measured in the peripheral 
blood. In contrast to antibodies, which 
are secreted into the serum as their site of 
action, B
MEM
 only pass through the blood 
on their way to the secondary lymphoid 
tissues where they reside and meet their 
antigen. Further, detection of PCs and 
B
MEM
 in peripheral blood may be limited 
by the sensitivity of the available assays, 
and some responses especially in young 
children may be below the limit of detec-
tion. The reliability of the assays used 
to measure B cell frequency is also an 
important consideration. Data indicate 
that the cultured ELISpot assay for the 
detection of B
MEM
 is reliable across opera-
tors and laboratories (Trück et al., unpub-
lished observations), however protocols 
may need to be standardized before data 
from multiple centers can be compared. 
A further challenge is the identifica-
tion of the B cell subsets involved in the 
response to vaccination. T-dependent and 
T-independent antigens induce different 
subsets of B cells,15,49 but the mechanisms 
by which each antigen drives its signature 
B cell phenotype is unclear, as is the con-
tribution of each subset to the mainte-
nance of serum antibody. Identification of 
the subsets involved may allow prediction 
of the duration of protection and clinical 
outcomes such as efficacy and carriage 
using early B cell responses as a surrogate 
marker of immunity. An understanding 
of the signals influencing the induction 
of each subset may lead to the develop-
ment of new vaccine strategies, which are 
more effective at preventing carriage and 
maintaining herd immunity. In conclu-
sion, B cells are key players in the induc-
tion and maintenance of vaccine-induced 
immunity. A better understanding of the 
phenotype and role of the B cell subsets 
involved has the potential to provide a 
useful new tool for predicting the effec-
tiveness and duration of vaccine-induced 
immunity.
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